NFIB Endorses Legislation Allowing Prescription Drug Reimportation

Main Category: Pharma Industry / Biotech Industry
Also Included In: Pharmacy / Pharmacist
Article Date: 15 Aug 2007 - 8:00 PST

email to a friend   printer friendly   view / write opinions   rate article

The National Federation of Independent Business has announced its endorsement of legislation (S 242 and HR 380) that would allow the purchase of lower-cost, FDA-approved drugs from other nations, CQ HealthBeat reports (CQ HealthBeat, 8/10).

The legislation would allow consumers, pharmacies and wholesalers to purchase FDA-approved prescription drugs that are manufactured at FDA-inspected facilities in 19 industrialized nations. Under the legislation, which would establish a regulatory framework for reimportation, FDA would regulate shipments of prescription drugs reimported into the U.S. for commercial or personal use. The bill also would require FDA to inspect Canadian prescription drug exporters 12 times annually (Kaiser Daily Health Policy Report, 5/8).

In its endorsement letter, NFIB wrote that the legislation "secures a framework for the safe and legal importation of prescription drugs," adding that it "is pleased that your legislation includes specific requirements that ensure that every imported drug meets U.S. safety standards." More than 50 consumer, labor and other organizations have endorsed the bills, which would save U.S. residents an estimated $50 billion over the next 10 years, according to advocates. Opponents of the legislation, including the Pharmaceutical Research and Manufacturers of America, claim allowing drug reimportation would open the nation's drug supply to counterfeiters (CQ HealthBeat, 8/10).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.